SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

$HSIC
Medical Specialities
Health Care
Get the next $HSIC alert in real time by email
SC 13G/A 1 hsica5_20823.htm LONGVIEW PARTNERS (GUERNSEY) LIMITED hsica5_20823.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 5)*
Henry Schein, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
US8064071025
(CUSIP Number)
December 31, 2022
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[X] Rule 13d-1(b)
[   ] Rule 13d-1(c)
[   ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
CUSIP No.: US8064071025
       
1
NAME OF REPORTING PERSON
Longview Partners (Guernsey) Limited
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [   ]
(b) [   ]
3 SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
Channel Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
SOLE VOTING POWER
6
SHARED VOTING POWER
3,669,916
7
SOLE DISPOSITIVE POWER
8
SHARED DISPOSITIVE POWER
7,015,011
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,015,011
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[   ]
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.18%
12
TYPE OF REPORTING PERSON
KC & IA
CUSIP No.: US8064071025
       
1
NAME OF REPORTING PERSON
Longview Partners LLP
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [   ]
(b) [   ]
3 SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
United Kingdom
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
SOLE VOTING POWER
6
SHARED VOTING POWER
3,669,916
7
SOLE DISPOSITIVE POWER
8
SHARED DISPOSITIVE POWER
7,015,011
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,015,011
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[   ]
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.18%
12
TYPE OF REPORTING PERSON
IA & PN
CUSIP No.: US8064071025
       
1
NAME OF REPORTING PERSON
Longview Partners (UK) Limited
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [   ]
(b) [   ]
3 SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
United Kingdom
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
SOLE VOTING POWER
6
SHARED VOTING POWER
3,669,916
7
SOLE DISPOSITIVE POWER
8
SHARED DISPOSITIVE POWER
7,015,011
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,015,011
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[   ]
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.18%
12
TYPE OF REPORTING PERSON
HC
CUSIP No.: US8064071025
ITEM 1(a). NAME OF ISSUER:
Henry Schein, Inc.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
135 Duryea Road
Melville, NY 11747
ITEM 2(a). NAME OF PERSON FILING:
Longview Partners (Guernsey) Limited
Longview Partners LLP
Longview Partners (UK) Limited
(Collectively referred to hereafter as "Longview Partners")
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Longview Partners (Guernsey) Limited
PO Box 559
Mill Court
La Charroterie
St Peter Port
Guernsey
GY1 6JG

Longview Partners (UK) Limited and Longview Partners LLP are both located at:
SavoyStrand
105 Strand
London WC2R 0AA
ITEM 2(c). CITIZENSHIP:
Longview Partners (Guernsey) Limited is a Guernsey registered company
Longview Partners LLP is a UK limited liability partnership
Longview Partners (UK) Limited is a UK registered company
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock
ITEM 2(e). CUSIP NUMBER:
US8064071025
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
(a)
[ ]
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
(b)
[ ]
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
[ ]
Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
[ ]
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
(e)
[X]
An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
(f)
[ ]
An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
(g)
[X]
A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
(h)
[ ]
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
[ ]
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
[ ]
A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
(k)
[ ]
Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
Longview Partners (Guernsey) Limited is an investment advisor registered under section 203 of the Investment Advisors Act of 1940.

Longview Partners (UK) Limited is 100% owned by Longview Partners (Guernsey) Limited.

Longview Partners (UK) Limited is the managing member of Longview Partners LLP.
ITEM 4. OWNERSHIP
(a) Amount beneficially owned:
7,015,011
(b) Percent of class:
5.18%
(c) Number of shares as to which the person has:
(i) sole power to vote or to direct the vote:
Longview Partners (Guernsey) Limited :

Longview Partners LLP :

Longview Partners (UK) Limited :
(ii) shared power to vote or to direct the vote:
Longview Partners (Guernsey) Limited : 3,669,916

Longview Partners LLP : 3,669,916

Longview Partners (UK) Limited : 3,669,916
(iii) sole power to dispose or direct the disposition of:
Longview Partners (Guernsey) Limited :

Longview Partners LLP :

Longview Partners (UK) Limited :
(iv) shared power to dispose or to direct the disposition of:
Longview Partners (Guernsey) Limited : 7,015,011

Longview Partners LLP : 7,015,011

Longview Partners (UK) Limited : 7,015,011
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
The shares reported herein have been acquired on behalf of discretionary clients of Longview Partners. Persons other than Longview Partners are entitled to receive dividends from, and proceeds from the sale of, those shares. None of those persons to the knowledge of Longview Partners has an economic interest in more than 5% of the class.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
Longview Partners LLP
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
As per Items 2(a) & 3 above
ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
ITEM 10. CERTIFICATION:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
CUSIP No.: US8064071025
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
February 08 2023
Longview Partners (Guernsey) Limited
By:
/s/ Stuart J Tostevin
Name:
Stuart J Tostevin
Title:
Compliance Officer
February 08 2023
Longview Partners LLP
By:
/s/ Sheila Tickner
Name:
Sheila Tickner
Title:
Head of Compliance
February 08 2023
Longview Partners (UK) Limited
By:
/s/ Lucy-Ellen Berwick
Name:
Lucy-Ellen Berwick
Title:
Company Secretary
Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
Get the next $HSIC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HSIC

DatePrice TargetRatingAnalyst
2/14/2025$80.00Equal Weight
Wells Fargo
1/6/2025$69.00 → $84.00Underperform → Buy
BofA Securities
12/4/2024$75.00Neutral
Mizuho
7/22/2024$81.00 → $92.00Neutral → Outperform
Robert W. Baird
2/26/2024$78.00Market Perform
Leerink Partners
12/12/2023$71.00 → $82.00Neutral → Overweight
JP Morgan
11/10/2023$70.00Hold → Buy
Stifel
8/8/2022$80.00Sell → Neutral
UBS
More analyst ratings

$HSIC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on

    $HSIC
    Medical Specialities
    Health Care
  • Henry Schein Received Validation of Net-Zero Science-Based Targets

    Company Commits to Science-Based Targets to Guide Pathway for Achieving Net-Zero Emissions by 2050 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Science Based Targets initiative (SBTi) has approved the Company's near-term and long-term science-based emissions reduction targets and has verified Henry Schein's net-zero science-based target by 2050. "Having joined the Business Ambition for 1.5⁰C initiative in 2021, Henry Schein is pleased to fulfill our commitment to set net-zero emissions reduction targets. Sustainability is deeply rooted in our corporate culture, and we unde

    $HSIC
    Medical Specialities
    Health Care
  • Henry Schein Will Showcase a Selection of the Company's Comprehensive Solutions for Oral Health Professionals at the 2025 International Dental Show

    Media roundtable sessions: "Conversations with Henry Schein: Exploring the Present and Future of Oral Health" will take place to discuss digitalization in dentistry; Henry Schein will also feature "FDI's Integrated Electronic Health Records Project." The Company will present an expansive portfolio of products and solutions, designed to help oral health professionals enhance practice efficiency and the patient experience, and will offer endodontic hands-on courses with Key Opinion Leaders at the booth. Henry Schein, Inc. (NASDAQ:HSIC) will showcase a selection of its comprehensive business and practice solutions, and provide perspectives on the future of dentistry, during the 2025 Inter

    $HSIC
    Medical Specialities
    Health Care

$HSIC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HSIC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HSIC
SEC Filings

See more

$HSIC
Leadership Updates

Live Leadership Updates

See more
  • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    $BAX
    $BMRN
    $EMBC
    $HSIC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities
  • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

    $BAX
    $BMRN
    $EMBC
    $HSIC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities
  • Give Kids A Smile Program Celebrates 23rd Year of Providing Free Oral Health Care Services to Underserved Children

    The American Dental Association Foundation's Initiative, with Exclusive National Sponsors Henry Schein and Colgate-Palmolive, Continues to Expand Its Reach, With Nearly 325,500 Children Expected to Receive Care Throughout 2025 The American Dental Association Foundation (ADA Foundation) is celebrating the 23rd year of its Give Kids A Smile® (GKAS) program, which officially launched on Friday, February 7, at the 2025 national kick-off event at Meharry Medical College School of Dentistry. Since its national launch in 2003, GKAS volunteers have provided free oral health education and services to more than 9.5 million underserved children in the U.S. This press release features multimedia. Vi

    $CL
    $HSIC
    Package Goods/Cosmetics
    Consumer Discretionary
    Medical Specialities
    Health Care

$HSIC
Financials

Live finance-specific insights

See more
  • Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on

    $HSIC
    Medical Specialities
    Health Care
  • Henry Schein Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Detailed 2025 Financial Guidance

    Fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19 Fourth-quarter 2024 operating cash flow of $204 million; full-year 2024 operating cash flow of $848 million, up $348 million compared with 2023 2025 non-GAAP diluted EPS expected to be in the range of $4.80 to $4.94 with mid-single digit 2025 Adjusted EBITDA growth Announces new reportable segments to provide more meaningful information for investors Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter and full year ended December 28, 2024. The financial result

    $HSIC
    Medical Specialities
    Health Care
  • Henry Schein Announces Strategic Investment by KKR, Board Changes and Provides Preliminary Unaudited Financial Results and 2025 Financial Guidance

    KKR to become 12% common shareholder in Henry Schein Henry Schein and KKR to collaborate on range of value creation opportunities Two KKR representatives with deep sector experience to join the Henry Schein Board as independent directors Separately, Robert J. Hombach, who brings extensive financial and strategic experience in health care, has joined the Henry Schein Board as an independent director Announces preliminary unaudited fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19, and preliminary 2025 financial guidance for full-year non-GAAP EPS of low to mid single digit growth In addition, Henry Schein has increased its share repurchase progra

    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance

$HSIC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more